Portada›Jueves 2 de octubre de 2025

Biomédicas del NASDAQ ante la SEC, jueves 2 de octubre de 2025

Los 27 documentos que 19 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← miércoles 1 de octubre de 2025 · viernes 3 de octubre de 2025 →

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Emisiones y dilución

1. PALIPALISADE BIO, INC.424B4Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …material used in our clinical trial. 24 Risks Related to Our Financial Operations We have expressed substantial doubt about our ability to continue as a going concern. Management has determined that there is substantial doubt about our ability to continue as a going concern for a period of one year following the issuance of our most recent financial statements. This determination was based on conditions and events, considered in the aggregate, that raise substantial doubt…

   En el documentoContrasplit de accionestexto original ▸

   …bid price of at least $1.00. In October 2023, we were notified that we were no longer in compliance with the Minimum Bid Price Requirement and had 180 days to cure such deficiency. On April 5, 2024, we effected a 1-for-15 reverse stock split and we were notified by the Nasdaq Stock Market that as of April 19, 2024, we were back in compliance with the Minimum Bid Price Requirement. On April 30, 2025, we received the Notice from Nasdaq advising…

   En el documentoDebilidad material en el control internotexto original ▸

   …profitability. Failure to remediate a material weakness in internal controls over financial reporting could result in material misstatements in our consolidated financial statements. Our management has identified a material weakness in our internal control over financial reporting. The material weakness was due to a lack of controls in the financial closing and reporting process, including a lack of segregation of duties and the…
2. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …68. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On October 1, 2025, the closing sale price per warrant of our Public Warrants was $0.23. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
3. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …68. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On October 1, 2025, the closing sale price per warrant of our Public Warrants was $0.23. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
4. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …68. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On October 1, 2025, the closing sale price per warrant of our Public Warrants was $0.23. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
5. BIOABioAge Labs, Inc.S-3Capacidad de emisión registradaEDGAR
6. BIOABioAge Labs, Inc.S-3Capacidad de emisión registradaEDGAR
7. IVVDInvivyd, Inc.S-3Capacidad de emisión registradaEDGAR
8. KZIAKAZIA THERAPEUTICS LTD424B3Prospecto suplementario o de reventaEDGAR
9. KZIAKAZIA THERAPEUTICS LTD424B3Prospecto suplementario o de reventaEDGAR
10. KZIAKAZIA THERAPEUTICS LTD424B3Prospecto suplementario o de reventaEDGAR
11. TCRTAlaunos Therapeutics, Inc.S-3/ACapacidad de emisión registrada (enmienda)EDGAR

Participaciones y control

1. COCPCocrystal Pharma, Inc.SC 13D/ACambio en participación significativaEDGAR
2. KALAKALA BIO, Inc.SC 13D/ACambio en participación significativaEDGAR
3. SCLXScilex Holding CoSC 13DCambio en participación significativaEDGAR

Informes y hechos relevantes

1. ACOGAlpha Cognition Inc.8-KNuevo acuerdo materialEDGAR
2. BCDABioCardia, Inc.8-KOtros hechos relevantesEDGAR
3. BOLTBolt Biotherapeutics, Inc.8-KOtros hechos relevantesEDGAR
   En el documentoRecorte de plantilla o reestructuracióntexto original ▸

   …Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 • Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026 • Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, CA, October 1, 2025 – Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of…
4. CRVSCorvus Pharmaceuticals, Inc.8-KCambio en el consejo o la direcciónEDGAR
5. DYNDyne Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
6. ENGNenGene Therapeutics Inc.8-K/ACambio en el consejo o la direcciónEDGAR
7. ENGNenGene Therapeutics Inc.8-KCambio en el consejo o la direcciónEDGAR
8. FDMT4D Molecular Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
9. HYPDHYPERION DEFI, INC.8-KCambio en el consejo o la direcciónEDGAR
10. IMDXInsight Molecular Diagnostics Inc.8-KCambio en el consejo o la direcciónEDGAR
11. KALAKALA BIO, Inc.8-K/ACambio en el consejo o la direcciónEDGAR
12. TSHATaysha Gene Therapies, Inc.8-KOtros hechos relevantesEDGAR
    En el documentoDesignación de terapia innovadora (breakthrough)texto original ▸

    …focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSHA-102, an intrathecally delivered AAV9 gene therapy with disease modifying potential, for the treatment of Rett syndrome. Additionally, the Company announced that it has finalized alignment with…
13. TTRXTurn Therapeutics Inc.8-KNuevo acuerdo materialEDGAR

← miércoles 1 de octubre de 2025 · viernes 3 de octubre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.